1 / 1

Combination Therapy for Endometrial Carcinoma

Lenvatinib specifically is a multikinase inhibitor of VEGFR1, VEGFR2, & VEGFR3, and other receptor tyrosine kinases, although the drug Pembrolizumab is an antibody targeting PD-1. A combination of pembrolizumab and lenvatinib is used to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other organs of the body or that can't be treated through surgery or radiation therapy.<br>The recommended dose of this combination drug therapy should be administered as per the words given by a healthcare professional. <br>

23914
Download Presentation

Combination Therapy for Endometrial Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CombinationTherapyofPembrolizumabandLenvatinibShowsPromisingOSinOrderToTreatAdvancedEndometrialCancerCombinationTherapyofPembrolizumabandLenvatinibShowsPromisingOSinOrderToTreatAdvancedEndometrialCancer Combinationtherapycomprisinglenvatinibandpembrolizumabtogethershowedthepromisingantitumoractivityinpatientswithadvancedendometrialcancerthatprogressedthroughsystemictherapy,regardlessofthetumorMSI(MicrosatelliteInstability)status. AccordingtoVickyMakker,MD,MemorialSloanKetteringCancerCenter,NewYork,andcolleagues,“Patientswiththeadvancedendometrialcarcinomahavelimitedtreatmentoptions.” VickyMakker,andcolleaguessharedfindingsfromaprimaryefficacyanalysisofthepatientswiththeadvancedendometrialcancergiventhecombinationtherapycomprisedlenvatinibandpembrolizumabinanongoingphase-1b/2clinicalinvestigation. Theenrolledpatientswereadministeredlenvatinib20mgonceinadaytogetherwithpembrolizumab200mg(keytruda)onceevery3-weeksin3-weekcycles. Theprimaryendpointoftheinvestigationwasthe24weekORR,andthesecondaryefficacyendpointsincludedtheresponseduration,PFS,andOS(OverallSurvival). Asofthepointofdatacutoff,atotalof108patientswereenrolledintheinvestigation,andfollow-uphadcontinuedforamedianofaround18.7months. Eventually,theobjectiveresponserateamongtheseenrolledpatientsatweek24wasnotedas38.0%(95%CI,28.8%to47.8%). Amidparticularpopulationsofpatientswithmicrosatelliteinstabilityhightumors(n=11)andmicrosatellitestabletumors(n=94),the24-weekobjectiveresponserateswere63.6%(95%CI,30.8%to89.1%)and36.2%(95%CI,26.5%to46.7%),respectively. Unconcernedofthetumormicrosatelliteinstabilitystatus,pretreatedpatientshadamedianresponsedurationof21.2months(95%CI,7.6monthstonotestimable),medianprogressionfreesurvivalof7.4months(95%CI,5.3to8.7months),andthemedianoverallsurvivalwasnotedas16.7months(15monthstonotestimable). DrMakker&colleaguesconcludedthat,“Thecombinationtherapycomprisedlenvatinibandpembrolizumabdemonstratedthepromisingantitumoractivityinpatientswithadvancedendometrialcarcinomawhohaveexperienceddiseaseprogressionfollowingpriorsystemictherapy,regardlessoftumormicrosatelliteinstabilitystatus.” Source:https://theindianpharma.wordpress.com/2021/03/31/combination -therapy-of-pembrolizumab-and-lenvatinib-shows-promising-os-in-order-to-treat-advanced-endometrial-cancer/

More Related